English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Strontium 89 (Sr89), a beta-emitter particle that precipitates in bone, has a palliative role in the treatment of painful bony metastases in androgen-resistant prostate cancer (ARPC) patients. Questionable additional benefit has been reported when it was combined with chemotherapy. Aim: To evaluate the efficacy of Sr89 given in combination with gemcitabine in ARPC patients with painful bony metas-

Strontium 89 Combined with Gemcitabine in Androgen-Resistant Prostate Cancer: Results of a Phase I-II Study